<html><body><h2>Case: 1943308</h2><h3> CDS Time: 1987-09-15</h3>
<patient name=1943308>
87.0 year old White_Non-Hispanic Female
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">87</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Calcium</td><td width="200">9</td><td width="200">1987-3-4</td></tr>
<tr><td width="200">Alkaline_phosphatase</td><td width="200">86</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">LDL_Cholesterol</td><td width="200">100</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">Chloride</td><td width="200">103.0</td><td width="200">1987-3-4</td></tr>
<tr><td width="200">HDL_Cholesterol</td><td width="200">44</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">Diastolic_BP</td><td width="200">61</td><td width="200">1987-9-15</td></tr>
<tr><td width="200">B 12</td><td width="200">217.0</td><td width="200">1984-7-13</td></tr>
<tr><td width="200">Weight</td><td width="200">140</td><td width="200">1987-9-15</td></tr>
<tr><td width="200">HbA1C</td><td width="200">11</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">Triglycerides</td><td width="200">236</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">Urine_ALB/CREAT_RATIO_spot</td><td width="200">25</td><td width="200">1985-1-12</td></tr>
<tr><td width="200">Urine_Alb/creat_Ratio_24h</td><td width="200">25</td><td width="200">1985-1-12</td></tr>
<tr><td width="200">Total_Cholesterol</td><td width="200">173</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">SGOT</td><td width="200">51</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">Systolic_BP</td><td width="200">149</td><td width="200">1987-9-15</td></tr>
<tr><td width="200">Total_Bilirubin</td><td width="200">0</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">Height</td><td width="200">65</td><td width="200">1987-7-25</td></tr>
<tr><td width="200">Potassium</td><td width="200">5</td><td width="200">1987-3-4</td></tr>
<tr><td width="200">Cholesterol</td><td width="200">173</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">BUN</td><td width="200">29</td><td width="200">1987-3-4</td></tr>
<tr><td width="200">HCT</td><td width="200">44</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">HGB</td><td width="200">15</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">Sodium</td><td width="200">136</td><td width="200">1987-3-4</td></tr>
<tr><td width="200">Albumen</td><td width="200">3</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">Creatinine</td><td width="200">1.8</td><td width="200">1987-3-4</td></tr>
<tr><td width="200">UrineAlbumin_24H</td><td width="200">28</td><td width="200">1985-1-12</td></tr>
<tr><td width="200">Glycosylated_Hemoglobin</td><td width="200">11</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">UrineAlbumin_SPOT</td><td width="200">28</td><td width="200">1985-1-12</td></tr>
<tr><td width="200">Pulse</td><td width="200">80</td><td width="200">1987-9-15</td></tr>
<tr><td width="200">PLT</td><td width="200">221</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">WBC</td><td width="200">9</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">eGFR</td><td width="200">28</td><td width="200">1987-3-4</td></tr>
<tr><td width="200">target_HBA1c</td><td width="200">7.0</td><td width="200">1987-5-3</td></tr>
<tr><td width="200">SGPT</td><td width="200">41</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">Sinoatrial node dysfunction</td><td width="200"></td><td width="200">1987-8-22</td></tr>
<tr><td width="200">Liver_Disease</td><td width="200"></td><td width="200">1987-8-5</td></tr>
<tr><td width="200">Race</td><td width="200">White_Non-Hispanic</td><td width="200"></td></tr>
<tr><td width="200">Sex</td><td width="200">Female</td><td width="200"></td></tr>
<tr><td width="200">Hypertension</td><td width="200"></td><td width="200">1987-2-15</td></tr>
<tr><td width="200">Atrial_Fibrillation</td><td width="200"></td><td width="200">1987-8-22</td></tr>
<tr><td width="200">DM-Type2</td><td width="200"></td><td width="200">1987-5-3</td></tr>
<tr><td width="200">PVD</td><td width="200"></td><td width="200">1987-2-15</td></tr>
<tr><td width="200">Pacemaker</td><td width="200"></td><td width="200">1987-8-22</td></tr>
<tr><td width="200">Disorders Lipid Metabolism</td><td width="200"></td><td width="200">1987-8-22</td></tr>
<tr><td width="200">Myocardial_Infarction</td><td width="200"></td><td width="200">1987-8-22</td></tr>
</table>
<p><b>Medications:</b> glyburide(10.0) aspirin(325.0) metformin(0.0) amiodarone(200.0) 
<p><b>Problems:</b> <table>
<tr><td width="200"><b>Problem Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr><td width="200">Sinoatrial node dysfunction</td>
<td width="200">1987-08-22</td>
<td width="200"> Sinoatrial node dysfunction()</td></tr>
<tr><td width="200">CRI</td>
<td width="200"></td>
<td width="200"> Renal Insufficiency[Creatinine(1.8/1987-3-4) && Sex(Female) && Creatinine(1.8/1987-3-4)]()</td></tr>
<tr><td width="200">Isolated_Systolic_Hypertension</td>
<td width="200"></td>
<td width="200"> Isolated Systolic Hypertension[Treatment_Systolic_BP(149/null) && Treatment_Diastolic_BP(61/null)]()</td></tr>
<tr><td width="200">Target_Organ_Damage_Clinical_Cardiovascular_Disease</td>
<td width="200"></td>
<td width="200"> TOD/CCD[presence of myocardial infarction]()</td></tr>
<tr><td width="200">Isolated_Systolic_Hypertension K >=3.5</td>
<td width="200"></td>
<td width="200"> Isolated Systolic Hypertension[presence of isolated systolic hypertension && Potassium(4.6/1987-3-4)]()</td></tr>
<tr><td width="200">Dyslipidemia Lab criteria</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab criteria[Triglycerides(236.0/1987-1-18)]()</td></tr>
<tr><td width="200">On Amiodarone</td>
<td width="200"></td>
<td width="200"> Amiodarone[amiodarone]()</td></tr>
<tr><td width="200">Diabetes WITHOUT proteinuria/renal manifestations</td>
<td width="200"></td>
<td width="200"> Diabetes[presence of diabetes mellitus && Absence of diabetic with renal manifestations && Absence of diabetic nephropathy && Absence of diabetic nephrosis && Proteinuria equals trace or above && Absence of ARB]()</td></tr>
<tr><td width="200">MI (BP not controlled)</td>
<td width="200"></td>
<td width="200"> Myocardial Infarction[BP not adequately controlled based on most recent BPTreatment_Systolic_BP(149/null) && presence of myocardial infarction]()</td></tr>
<tr><td width="200">DM and BP not controlled</td>
<td width="200"></td>
<td width="200"> Diabetes[presence of DM && BP not adequately controlled based on most recent BPTreatment_Systolic_BP(149/null)]()</td></tr>
<tr><td width="200">Major Cardiovascular Risk Factor</td>
<td width="200"></td>
<td width="200"> Major Cardiovascular Risk Factor[Sex(Female) && Age(87.0/1970-1-1)]()</td></tr>
<tr><td width="200">Dyslipidemia Lab or ICD9</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab or ICD9[presence of dyslipidemia lab criteria]()</td></tr>
<tr><td width="200">CKD by eGFR</td>
<td width="200"></td>
<td width="200"> CKD by eGFR[eGFR(28.0/1987-3-4)]()</td></tr>
<tr><td width="200">CKD by eGFR or ICD9 codes</td>
<td width="200"></td>
<td width="200"> CKD[eGFR(28.0/1987-3-4)]()</td></tr>
<tr><td width="200">No med and K>=3.5</td>
<td width="200"></td>
<td width="200"> 1st line drug for hypertension[Potassium(4.6/1987-3-4) && Antihypertensive_Agents]()</td></tr>
<tr><td width="200">Age > 65</td>
<td width="200"></td>
<td width="200"> age > 65 years[Age(87.0/1970-1-1)]()</td></tr>
<tr><td width="200">On 1 drug and there exists contraindicated drug or a compelling drug not given</td>
<td width="200"></td>
<td width="200"> On 1 drug and there exists contraindicated drug or a compelling drug not given[there exists a compellingly indicated drug that is not already given]()</td></tr>
<tr><td width="200">Hypertension with MI and K>=3.5</td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(4.6/1987-3-4) && presence of MI]()</td></tr>
<tr><td width="200">Hepatobiliary_Diseases</td>
<td width="200">1987-08-05</td>
<td width="200"> Liver_Disease()</td></tr>
<tr><td width="200">CCS-7.4</td>
<td width="200">1987-02-15</td>
<td width="200"> PVD()</td></tr>
<tr><td width="200">CCS-7.2</td>
<td width="200">1987-08-22</td>
<td width="200"> Myocardial_Infarction()</td></tr>
<tr> <td width="200"></td>
<td width="200">1987-08-22</td>
<td width="200"> Sinoatrial node dysfunction()</td></tr>
<tr> <td width="200"></td>
<td width="200">1987-08-22</td>
<td width="200"> Atrial_Fibrillation()</td></tr>
<tr><td width="200">Hypertension_Inclusive</td>
<td width="200">1987-02-15</td>
<td width="200"> Hypertension()</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(4.6/1987-3-4) && presence of MI]()</td></tr>
<tr><td width="200">Pacemaker</td>
<td width="200">1987-08-22</td>
<td width="200"> Pacemaker()</td></tr>
<tr><td width="200">Metabolic&Nutritional_Diseases</td>
<td width="200">1987-08-22</td>
<td width="200"> Disorders Lipid Metabolism()</td></tr>
<tr><td width="200">Endocrine_Diseases</td>
<td width="200">1987-05-03</td>
<td width="200"> DM-Type2()</td></tr>
<tr><td width="200">Hypertension_Defined</td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(4.6/1987-3-4) && presence of MI]()</td></tr>
<tr><td width="200"> <b>Others</b></td>
<td width="200"></td>
<td width="200"> Race()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Sex()
</table><p>
</patient>
<h1 align="center">VA/JNC-VII Hypertension Guideline</h1>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(presence of diagnosis of hypertension && absence of renovascular disease && no diagnosis of pregnancy && Absense of Secondary Hypertension && absence of spinal cord injury && absence of narcolepsy && Not taking cyclosporine && Not taking spironolactone && Not taking minoxidil && absence of renovascular disease && absence of IHSS && Absence of Ascites && Not off guideline && not taking tacrolimus && absence of transplant recipient && Absence of a dialysis procedure code)</i>]
<li>Risk Group C (presence of TOD/CCD or DM): [because <i> presence of TOD/CCD or DM </i> evaluate to <b>true</b><i>(presence of DM)</i>]
</ul>
<b>Scenario choice:</b> not on drug therapy
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> failed(Treatment_Systolic_BP(149/null))
<p><b>Messages by Types</b>
<ul>
<li><b>Recommendation</b>
<ul>
<li>Warning: creatinine value is greater than 1.5 mg/dL, upper limit of normal for males.
<li>The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.
</ul>
<li><b>Primary_Recommendation</b>
<ul>
<li>Recommend ADDING antihypertensive medication: BP ELEVATED based on most recent available BP; F/up 1month.
</ul>
<li><b>Assumption</b>
<ul>
<li>We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>not on antihypertensive medication consultation actions</b><br>
<ul>
<li><b>assumption  check presence of BP <font color=FF0000>preferred</font></b>(rule in criterion<i> diastolic BP or systolic BP absent</i> evaluate to <b> true</b> because <i>absence of diastolic BP</i>)])
We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.
<li><b>creatinine > ULN, check creatinine <font color=FF0000>preferred</font></b>(rule in criterion<i> creatinine > upper limit of normal</i> evaluate to <b> true</b> because <i>Creatinine(1.8/1987-3-4)</i>)])
Warning: creatinine value is greater than 1.5 mg/dL, upper limit of normal for males.
<li><b>Disclaimer <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.
</ul>
<li><b>no-drug-therapy-choices</b><br>
<ul>
<li><b>not on drug therapy, consider adding drug <font color=FF0000>preferred</font></b>(strict rule-in condition<i> BP not adequately controlled based on most recent BP</i> evaluate to <b> true</b> because <i>BP not adequately controlled based on most recent BPTreatment_Systolic_BP(149/null)</i>)])

Recommend ADDING antihypertensive medication: BP ELEVATED based on most recent available BP; F/up 1month.
</ul>
</ul>
<b>Considerations for adding drug: </b><ul><li>Thiazide Diuretic (HCTZ)<ul><li><font color=FF0000>Compelling indications:  CKD by eGFR or ICD9 codes(CKD[eGFR(28.0/1987-3-4)])  No med and K>=3.5(1st line drug for hypertension[Potassium(4.6/1987-3-4) && Antihypertensive_Agents])  Diabetes_Mellitus(DM-Type2) </font><li>Relative indications:  MI (BP not controlled)(Myocardial Infarction[BP not adequately controlled based on most recent BPTreatment_Systolic_BP(149/null) && presence of myocardial infarction]) <li>HCTZ dosing message and creatinine<=2.0(HCTZ dose above 25 mg doesn't add to BP control for most patients and may lead to hypokalemia.)<li>Add HCTZ/BB diabetes, ACE compellingly indicated if proteinuria(If patient has proteinuria or renal manifestations of diabetes therapy with ACE inhibitor is strongly recommended.)<li>preference: preferred</ul><li>ACE Inhibitor (lisinopril)<ul><li><font color=FF0000>Compelling indications:  Diabetes_Mellitus(DM-Type2)  MI (BP not controlled)(Myocardial Infarction[BP not adequately controlled based on most recent BPTreatment_Systolic_BP(149/null) && presence of myocardial infarction])  CKD by eGFR or ICD9 codes(CKD[eGFR(28.0/1987-3-4)]) </font><li>adding ace inhibitor, check Cr and K, [Cr<=1.5(male) or Cr<=1.3(female)] and K<5.6(Check the patient's creatinine and potassium concentrations when prescribing  ACE Inhibitors.)<li>add ACE and Creatinine>1.3 (female)(ACE inhibitor is recommended because most recent creatinine is above 1.3mg/dl (upper normal limit for females), disregard if renal insufficiency is acute. Recheck creatinine and potassium concentration after starting ACE inhibitor therapy.)<li>MI (ACE) and JNC7 rec aldosterone antagonists(ACE Inhibitor is compellingly indicated for post MI by JNC7 and 2004 VA Guidelines, JNC7 also has aldosterone antagonists as a compelling indication for MI.)<li>Add ACE/ARB & CKD; alert creatinine rise(A stable increase of serum creatinine as much as 35% above baseline after ACEI or ARB initiation may be tolerated, as long as hyperkalemia does not occur. ACEI or ARB should be discontinued, or other potentially reversible causes of kidney failure investigated if progressive and rapid rise of serum creatinine continues. Since CKD is associated with progressive rise in creatinine over years, ACEI or ARB should not be discontinued for this situation, since these medications are renoprotective.)<li>preference: preferred</ul><li>Cardioselective Beta Blocker (metoprolol)<ul><li><font color=FF0000>Compelling indications:  Myocardial_Infarction(Myocardial_Infarction) </font><li>Relative indications:  Atrial_Fibrillation(Atrial_Fibrillation)  CKD by eGFR or ICD9 codes(CKD[eGFR(28.0/1987-3-4)])  Diabetes_Mellitus(DM-Type2) <li>Relative contraindications:  On Amiodarone(Amiodarone[amiodarone]) <li>Add Beta blocker and DM(Beta blockers may diminish symptoms of and recovery from hypoglycemia and should be used with caution in patients who are prone to hypoglycemia.)<li>Add Beta blocker and PVD(Beta blockers may exacerbate symptoms of peripheral vascular disease (PVD). It is important to follow the effect on your individual patient.)<li>sinoatrial node dysfunction and pacemaker BB(Beta adrenergic receptor antagonists may worsen bradycardia in patients with sinoatrial node dysfunction. This patient's pacemaker, if functioning properly, should protect against adverse events.)<li>amiodarone add beta blocker(Concurrent use of amiodarone and beta adrenergic receptor antagonist may result in excessive lowering of heart rate.)<li>Atrial fibrillation and add NDHP orBB(Management of  arrythmia is complex and may require consultation with specialist.)<li>betablocker dyslipidemia warning message(Beta blockers may have transient adverse effects on lipids in some patients.  Consider repeating lipid profile after maximal dosage of drug has been reached if appropriate.)<li>disclaimer about procedure reports delete(Diagnoses from EKG reports are not extracted. If patient has an arrythmia that is not shown in patient summary, please update problem list.)<li>Add HCTZ/BB diabetes, ACE compellingly indicated if proteinuria(If patient has proteinuria or renal manifestations of diabetes therapy with ACE inhibitor is strongly recommended.)<li>MI (BB)  and JNC7 rec aldosterone antag(Beta Adrenergic Receptor Antagonist is compellingly indicated for post MI by JNC7 and 2004 VA Guidelines, JNC7 also has aldosterone antagonists as a compelling indication for MI.)<li>preference: preferred</ul><li>Angiotensin II Receptor Blocker (irbesartan)<ul><li><font color=FF0000>Compelling indications:  CKD by eGFR or ICD9 codes(CKD[eGFR(28.0/1987-3-4)]) </font><li>Relative indications:  Diabetes_Mellitus(DM-Type2) <li>ARB II-check K and Cr(Check the patient's plasma creatinine and potassium concentrations when prescribing or increasing dose of  angiotensin II receptor blockers.)<li>Add ACE/ARB & CKD; alert creatinine rise(A stable increase of serum creatinine as much as 35% above baseline after ACEI or ARB initiation may be tolerated, as long as hyperkalemia does not occur. ACEI or ARB should be discontinued, or other potentially reversible causes of kidney failure investigated if progressive and rapid rise of serum creatinine continues. Since CKD is associated with progressive rise in creatinine over years, ACEI or ARB should not be discontinued for this situation, since these medications are renoprotective.)<li>preference: preferred</ul><li>DHP Calcium Channel Blocker (felodipine, nifedipine SA)<ul><li>Relative indications:  MI (BP not controlled)(Myocardial Infarction[BP not adequately controlled based on most recent BPTreatment_Systolic_BP(149/null) && presence of myocardial infarction])  Diabetes_Mellitus(DM-Type2) <li>preference: preferred</ul><li>(non-DHP) Calcium Channel Blocker (diltiazem)<ul><li>Relative indications:  Atrial_Fibrillation(Atrial_Fibrillation)  MI (BP not controlled)(Myocardial Infarction[BP not adequately controlled based on most recent BPTreatment_Systolic_BP(149/null) && presence of myocardial infarction])  CKD by eGFR or ICD9 codes(CKD[eGFR(28.0/1987-3-4)]) <li>Relative contraindications:  On Amiodarone(Amiodarone[amiodarone]) <li>sinoatrial node dysfunction + pacemaker+ diltiazem/verapamil(Diltiazem or verapamil may worsen bradycardia in patients with sinoatrial node dysfunction. This patient's pacemaker, if functioning properly, should protect against adverse events.)<li>Amiodarone add diltiazem('Concurrent use of amiodarone and diltiazem may result in excessive lowering of heart rate.)<li>Atrial fibrillation and add NDHP orBB(Management of  arrythmia is complex and may require consultation with specialist.)<li>disclaimer about procedure reports delete(Diagnoses from EKG reports are not extracted. If patient has an arrythmia that is not shown in patient summary, please update problem list.)<li>preference: preferred</ul><li>Potassium Sparing Diuretic <ul><li>preference: neutral<li>No comment</ul><li>Alpha Blocker (terazosin)<ul><li>preference: neutral<li>No comment</ul></ul></body></html>